Medicxi Links With Sosei Heptares For Orexin Agonist Vehicles
Executive Summary
After spending 12 months looking for promising orexin agonist candidates, asset-centric venture capitalist Medicxi finds answer close to home and commits up to €40M to create two companies underpinned by assets from Heptares Therapeutics.
You may also be interested in...
Genentech Signs Up Sosei Heptares GPCR Smarts For $1bn+ Deal
The companies have agreed to a multi-year, multi-target research collaboration and license deal to discover and develop medicines that modulate GPCR targets across a range of diseases.
Deal Watch: Roivant Spins Out Arvelle, Licenses Epilepsy Candidate From SK Biopharma
Already having launched several portfolio companies, Roivant goes a step further by spinning out CNS specialist Arvelle from Axovant. BI and IBM will incorporate blockchain technology in clinical trials, while AbbVie licenses multiple myeloma candidate from TeneoBio.
Deal Watch: Xencor Adds New Bispecific Partner In Agreement With Genentech
Genentech will pay $120m up front to co-develop Xencor’s preclinical IL-15 candidate; deal also includes IL-15 R&D. Taiho licenses lung cancer candidate to Cullinan; Celgene and Triphase partner again.